RxDoctor Payments Data

Melissa Burns, APRN

Nurse Practitioner · Cumberland, KYNPI 1922516426

Payments from drug & device makers

$1,382in general payments, 2019–2025

Across 83 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$356
  • Boehringer Ingelheim$291
  • Lilly USA, LLC$212
  • Astellas Pharma US Inc$174
  • AstraZeneca$150
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$78
  • plus $122 from 5 others

What the payments were for

  • Food & beverage$1,20887%
  • Education$17413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,382 in reported general payments places this provider in the 70th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,348
Medicare patients
20
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$17,968
VraylarCariprazine Hcl13$17,612
MounjaroTirzepatide16$16,744
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,692
EliquisApixaban16$11,268
TradjentaLinagliptin18$10,644
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,957
FarxigaDapagliflozin Propanediol11$7,477
Ventolin HfaAlbuterol Sulfate61$3,365
Albuterol Sulfate HfaAlbuterol Sulfate62$1,871
Colchicine11$775
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$743
Levothyroxine Sodium110$729
Hydroxyzine Hcl41$529
Tizanidine Hcl53$512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$67$17,96817 claims
AbbVieVraylar$12$17,61213 claims
Lilly USA, LLCMounjaro$212$16,74416 claims
AstraZenecaBreztri Aerosphere, Farxiga$150$15,43424 claims
GSKTrelegy Ellipta$13$13,69221 claims
PfizerEliquis$356$11,26816 claims
Boehringer IngelheimTradjenta$291$10,64418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Cumberland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →